Back to Search
Start Over
Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates.
- Source :
-
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2008 Jun 15; Vol. 14 (12), pp. 3942-7. - Publication Year :
- 2008
-
Abstract
- Purpose: Platelet concentrates are important for support of patients with malignancies requiring myelotoxic chemotherapy. During storage, 10% to 15% of platelets may become activated resulting in the release of alpha-granules, which contain growth factors. We hypothesize that, during storage, growth factors accumulate in the plasma, specifically platelet-derived growth factor, vascular endothelial growth factor (VEGF), transforming growth factor-beta, and fibroblast growth factor-2, which may adversely affect cancer patients.<br />Experimental Design: The concentrations of growth factors were measured by ELISA from the plasma of apheresis platelets serially throughout storage (days 1, 3, 5, and 7) and compared with concentrations in fresh plasma from healthy blood donors. Washing was evaluated as a method of growth factor removal, and an in vitro model of platelet transfusion in a patient receiving Bevacizumab (Avastin) using immunoprecipitation was employed to determine if Bevacizumab would be bound by the VEGF in apheresis platelets.<br />Results: VEGF, platelet-derived growth factor, and transforming growth factor-beta were increased on day 1 versus fresh plasma and throughout storage reaching a relative maximum at outdate (P < 0.01, day 5 or 7). Fibroblast growth factor-2 concentrations were significantly increased on day 7 alone versus day 1 or to fresh plasma (P < 0.01). Washing removed 41 +/- 11% to 56 +/- 2% of the growth factors. Bevacizumab effectively bound the VEGF from apheresis platelets, with significant amounts of VEGF remaining in the supernatant.<br />Conclusions: Significant amounts of growth factors are present in apheresis platelets due to the isolation procedures, and these concentrations increase over storage, which may be partially removed by washing. In addition, apheresis platelet transfusion could affect cancer treatment by binding monoclonal antibodies directed against growth factors of tumor origin.
- Subjects :
- Angiogenesis Inhibitors therapeutic use
Angiogenic Proteins analysis
Angiogenic Proteins blood
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Carcinogens analysis
Fibroblast Growth Factor 2 analysis
Fibroblast Growth Factor 2 blood
Humans
Intercellular Signaling Peptides and Proteins analysis
Intercellular Signaling Peptides and Proteins blood
Platelet-Derived Growth Factor analysis
Transforming Growth Factor beta analysis
Transforming Growth Factor beta blood
Vascular Endothelial Growth Factor A analysis
Vascular Endothelial Growth Factor A blood
Vascular Endothelial Growth Factor A immunology
Angiogenic Proteins metabolism
Blood Preservation adverse effects
Carcinogens metabolism
Intercellular Signaling Peptides and Proteins metabolism
Plateletpheresis
Subjects
Details
- Language :
- English
- ISSN :
- 1078-0432
- Volume :
- 14
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publication Type :
- Academic Journal
- Accession number :
- 18559616
- Full Text :
- https://doi.org/10.1158/1078-0432.CCR-07-4824